Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
National Institutes of Health (NIH)
Total funding amount: $27,000,000 for FY 2026
Duration: Up to 5 years (2 years for R61 phase, 3 years for R33 phase)
To encourage pilot research developing and testing innovative psychosocial intervention approaches.
Mission of NIMH: Transform the understanding and treatment of mental illnesses through research.
Stakeholders: Higher education institutions, nonprofits, government agencies.
Beneficiaries: Individuals at risk for or suffering from mental disorders.
Eligible organization types include public/state controlled institutions of higher education, private institutions of higher education, nonprofits, for-profit organizations, small businesses, local governments, state governments, county governments, city or township governments, special district governments, Indian/Native American tribal governments, and eligible agencies of the federal government.
Non-domestic (non-U.S.) entities are also eligible to apply.
Eligible organizations can be based in the U.S. or be non-domestic entities.
Foreign components of U.S. organizations are allowed.
Focus on psychosocial intervention development consistent with NIMH's experimental therapeutic approach.
Projects must include a defined intervention target based on empirical evidence.
Application budgets are not limited but must reflect the actual needs of the proposed project.
Application due dates are set for various cycles, with the earliest submission date on January 18, 2025.
All applications are due by 5:00 PM local time of the applicant organization.
Applicants may submit more than one application, provided each is scientifically distinct.
The NIH will not accept duplicate or overlapping applications under review at the same time.
Applications must follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide.
Applications will be evaluated based on overall impact, significance, innovation, rigor, and feasibility.
Applications will undergo scientific peer review and receive a written critique.
Scientific and technical merit of the proposed project will be considered in funding decisions.
The grant requires clinical trials and emphasizes the experimental therapeutic approach.
High failure rates may be expected due to the innovative nature of the projects.
Demonstration of target engagement is crucial for progressing from the R61 to R33 phase.
Avoid submitting overlapping applications and ensure compliance with all application instructions.